PL3386509T3 - Zastosowanie kabergoliny w leczeniu schorzeń oczu wywołanych przez podwyższone poziomy śródbłonkopochodnego czynnika wzrostu naczyń - Google Patents
Zastosowanie kabergoliny w leczeniu schorzeń oczu wywołanych przez podwyższone poziomy śródbłonkopochodnego czynnika wzrostu naczyńInfo
- Publication number
- PL3386509T3 PL3386509T3 PL16831636T PL16831636T PL3386509T3 PL 3386509 T3 PL3386509 T3 PL 3386509T3 PL 16831636 T PL16831636 T PL 16831636T PL 16831636 T PL16831636 T PL 16831636T PL 3386509 T3 PL3386509 T3 PL 3386509T3
- Authority
- PL
- Poland
- Prior art keywords
- cabergoline
- treatment
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 229960004596 cabergoline Drugs 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415170A PL232974B1 (pl) | 2015-12-09 | 2015-12-09 | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
| PCT/IB2016/057483 WO2017098461A1 (en) | 2015-12-09 | 2016-12-09 | Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels |
| EP16831636.2A EP3386509B1 (en) | 2015-12-09 | 2016-12-09 | Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3386509T3 true PL3386509T3 (pl) | 2020-08-24 |
Family
ID=57909808
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL415170A PL232974B1 (pl) | 2015-12-09 | 2015-12-09 | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
| PL16831636T PL3386509T3 (pl) | 2015-12-09 | 2016-12-09 | Zastosowanie kabergoliny w leczeniu schorzeń oczu wywołanych przez podwyższone poziomy śródbłonkopochodnego czynnika wzrostu naczyń |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL415170A PL232974B1 (pl) | 2015-12-09 | 2015-12-09 | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180360820A1 (pl) |
| EP (1) | EP3386509B1 (pl) |
| CN (1) | CN108472294B (pl) |
| CA (1) | CA3007953C (pl) |
| DK (1) | DK3386509T3 (pl) |
| ES (1) | ES2761875T3 (pl) |
| HR (1) | HRP20192256T1 (pl) |
| IL (1) | IL259903B (pl) |
| LT (1) | LT3386509T (pl) |
| PL (2) | PL232974B1 (pl) |
| PT (1) | PT3386509T (pl) |
| RU (1) | RU2698728C1 (pl) |
| WO (1) | WO2017098461A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL241086B1 (pl) * | 2017-09-26 | 2022-08-01 | Oseka Maciej | Pergolid do zastosowania w leczeniu zakrzepu naczyń siatkówki i/lub zatoru naczyń siatkówki oraz kompozycja farmaceutyczna zawierająca pergolid |
| PL430675A1 (pl) * | 2019-07-23 | 2021-01-25 | Osęka Maciej | Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| SK13312000A3 (sk) * | 1998-03-27 | 2001-05-10 | Pharmacia And Upjohn Company | Použitie kabergolínu pri liečbe syndrómu nepokojných nôh |
| KR20060056417A (ko) * | 1998-05-15 | 2006-05-24 | 파마시아 앤드 업존 캄파니 엘엘씨 | 프라미펙솔의 신규 용도 |
| US20070155770A1 (en) * | 2006-01-03 | 2007-07-05 | Cedars-Sinai Medical Center | Treatment of anoragasmia or delayed orgasm |
| KR100923195B1 (ko) * | 2006-04-04 | 2009-10-22 | 고려대학교 산학협력단 | 도파민 ｄ2 수용체에 의한 도파민성 수용체 발달의 조절방법 및 이의 조성물 |
| RU2470635C2 (ru) * | 2007-05-11 | 2012-12-27 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза |
| WO2011069051A1 (en) * | 2009-12-04 | 2011-06-09 | Caliper Life Sciences, Inc. | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
-
2015
- 2015-12-09 PL PL415170A patent/PL232974B1/pl unknown
-
2016
- 2016-12-09 EP EP16831636.2A patent/EP3386509B1/en active Active
- 2016-12-09 LT LTEP16831636.2T patent/LT3386509T/lt unknown
- 2016-12-09 WO PCT/IB2016/057483 patent/WO2017098461A1/en not_active Ceased
- 2016-12-09 CN CN201680072556.9A patent/CN108472294B/zh not_active Expired - Fee Related
- 2016-12-09 RU RU2018124858A patent/RU2698728C1/ru active
- 2016-12-09 PL PL16831636T patent/PL3386509T3/pl unknown
- 2016-12-09 CA CA3007953A patent/CA3007953C/en active Active
- 2016-12-09 DK DK16831636.2T patent/DK3386509T3/da active
- 2016-12-09 HR HRP20192256TT patent/HRP20192256T1/hr unknown
- 2016-12-09 PT PT168316362T patent/PT3386509T/pt unknown
- 2016-12-09 US US16/060,517 patent/US20180360820A1/en not_active Abandoned
- 2016-12-09 ES ES16831636T patent/ES2761875T3/es active Active
-
2018
- 2018-06-07 IL IL259903A patent/IL259903B/en active IP Right Grant
-
2020
- 2020-03-31 US US16/836,168 patent/US11324740B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3007953C (en) | 2022-11-29 |
| CA3007953A1 (en) | 2017-06-15 |
| LT3386509T (lt) | 2020-01-27 |
| DK3386509T3 (da) | 2019-12-16 |
| CN108472294A (zh) | 2018-08-31 |
| US20180360820A1 (en) | 2018-12-20 |
| CN108472294B (zh) | 2021-07-13 |
| US20200222387A1 (en) | 2020-07-16 |
| HRP20192256T1 (hr) | 2020-03-06 |
| PL415170A1 (pl) | 2017-06-19 |
| ES2761875T3 (es) | 2020-05-21 |
| PL232974B1 (pl) | 2019-08-30 |
| EP3386509A1 (en) | 2018-10-17 |
| EP3386509B1 (en) | 2019-09-18 |
| IL259903B (en) | 2020-09-30 |
| WO2017098461A1 (en) | 2017-06-15 |
| PT3386509T (pt) | 2019-12-30 |
| US11324740B2 (en) | 2022-05-10 |
| RU2698728C1 (ru) | 2019-08-29 |
| IL259903A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252159A0 (en) | Methods and formulations for the treatment of diseases of the blood vessels of the eye | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| SI3122878T1 (sl) | MRNA terapija za zdravljenje očesnih bolezni | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| EP3137116A4 (en) | Dendrimer compositions and their use in treatment of diseases of the eye | |
| EP3030275A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
| EP3030276A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
| EP3060259A4 (en) | Methods of treating or preventing vascular diseases of the retina | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| EP3030274A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
| GB201417163D0 (en) | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | |
| HUE040373T2 (hu) | Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra | |
| IL251769A0 (en) | Methods for treating eye conditions | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| PL3049100T3 (pl) | Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznych | |
| IL248210A0 (en) | Methods and preparations for the treatment of blood vessel malformations | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| GB201503967D0 (en) | Biocompatible implants for use in tendon therapy | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| IL246587A0 (en) | Preparations for use in the treatment of allergic conditions | |
| LT3386509T (lt) | Kabergolino naudojimas gydant akių ligas, sukeltas padidėjusio kraujagyslių endotelio augimo faktoriaus lygio | |
| PL3229780T3 (pl) | Kompozycje okulistyczne do zastosowania w leczeniu zespołu suchego oka | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases | |
| HK1231747A1 (en) | Dendrimer compositions and their use in treatment of diseases of the eye |